Roffman Miller Associates Inc. PA Increases Holdings in Johnson & Johnson (NYSE:JNJ)

Roffman Miller Associates Inc. PA raised its stake in Johnson & Johnson (NYSE:JNJ) by 0.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 240,997 shares of the company’s stock after purchasing an additional 95 shares during the quarter. Johnson & Johnson comprises about 2.7% of Roffman Miller Associates Inc. PA’s investment portfolio, making the stock its 13th biggest position. Roffman Miller Associates Inc. PA’s holdings in Johnson & Johnson were worth $37,774,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. Brown Miller Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 3.1% in the third quarter. Brown Miller Wealth Management LLC now owns 18,097 shares of the company’s stock valued at $2,818,000 after purchasing an additional 545 shares during the period. Meridian Wealth Management LLC lifted its holdings in Johnson & Johnson by 79.6% in the 3rd quarter. Meridian Wealth Management LLC now owns 101,082 shares of the company’s stock worth $15,745,000 after buying an additional 44,786 shares in the last quarter. B.O.S.S. Retirement Advisors LLC boosted its position in Johnson & Johnson by 9.6% in the 3rd quarter. B.O.S.S. Retirement Advisors LLC now owns 20,333 shares of the company’s stock valued at $3,167,000 after buying an additional 1,773 shares during the last quarter. KFG Wealth Management LLC grew its stake in shares of Johnson & Johnson by 3.8% during the third quarter. KFG Wealth Management LLC now owns 4,575 shares of the company’s stock valued at $713,000 after acquiring an additional 168 shares in the last quarter. Finally, Nikulski Financial Inc. increased its position in shares of Johnson & Johnson by 11.0% during the third quarter. Nikulski Financial Inc. now owns 2,125 shares of the company’s stock worth $331,000 after acquiring an additional 210 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.5 %

Shares of NYSE JNJ opened at $146.84 on Tuesday. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97. The company has a market cap of $353.85 billion, a price-to-earnings ratio of 9.15, a price-to-earnings-growth ratio of 2.41 and a beta of 0.53. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. The stock’s 50 day simple moving average is $155.07 and its 200 day simple moving average is $155.23.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. The company had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. During the same period last year, the business posted $2.68 earnings per share. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. Equities research analysts expect that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be given a $1.24 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend is Monday, May 20th. This represents a $4.96 annualized dividend and a yield of 3.38%. Johnson & Johnson’s dividend payout ratio is 29.68%.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of recent analyst reports. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price objective for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Monday, April 15th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Royal Bank of Canada decreased their price objective on shares of Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating for the company in a report on Wednesday, April 17th. Finally, Morgan Stanley reduced their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 17th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $175.86.

Insider Buying and Selling at Johnson & Johnson

In related news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.